CCEL Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of 9.58% compared to Cryo-Cell International, Inc.'s net margin of 0.11%. Cryo-Cell International, Inc.'s return on equity of -- beat Astrana Health, Inc.'s return on equity of 1.85%.

Cryo-Cell International, Inc. has a consensus price target of $8.50, signalling upside risk potential of 149.27%. On the other hand Astrana Health, Inc. has an analysts' consensus of $36.8889 which suggests that it could grow by 35.82%. Given that Cryo-Cell International, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Astrana Health, Inc..

Cryo-Cell International, Inc. has a beta of 0.689, which suggesting that the stock is 31.12% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

Cryo-Cell International, Inc. has a quarterly dividend of $0.15 per share corresponding to a yield of 19.06%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International, Inc. pays 510.2% of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Cryo-Cell International, Inc. quarterly revenues are $7.8M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Cryo-Cell International, Inc.'s net income of $749.4K is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, Cryo-Cell International, Inc.'s price-to-earnings ratio is 498.00x while Astrana Health, Inc.'s PE ratio is 142.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International, Inc. is 0.87x versus 0.46x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

biote Corp. has a net margin of 9.58% compared to Cryo-Cell International, Inc.'s net margin of 19.22%. Cryo-Cell International, Inc.'s return on equity of -- beat biote Corp.'s return on equity of --.

Cryo-Cell International, Inc. has a consensus price target of $8.50, signalling upside risk potential of 149.27%. On the other hand biote Corp. has an analysts' consensus of $4.21 which suggests that it could grow by 90.59%. Given that Cryo-Cell International, Inc. has higher upside potential than biote Corp., analysts believe Cryo-Cell International, Inc. is more attractive than biote Corp..

Cryo-Cell International, Inc. has a beta of 0.689, which suggesting that the stock is 31.12% less volatile than S&P 500. In comparison biote Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cryo-Cell International, Inc. has a quarterly dividend of $0.15 per share corresponding to a yield of 19.06%. biote Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International, Inc. pays 510.2% of its earnings as a dividend. biote Corp. pays out -- of its earnings as a dividend.

Cryo-Cell International, Inc. quarterly revenues are $7.8M, which are smaller than biote Corp. quarterly revenues of $48M. Cryo-Cell International, Inc.'s net income of $749.4K is lower than biote Corp.'s net income of $9.2M. Notably, Cryo-Cell International, Inc.'s price-to-earnings ratio is 498.00x while biote Corp.'s PE ratio is 2.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International, Inc. is 0.87x versus 0.40x for biote Corp.. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners, Inc. has a net margin of 9.58% compared to Cryo-Cell International, Inc.'s net margin of -20.12%. Cryo-Cell International, Inc.'s return on equity of -- beat P3 Health Partners, Inc.'s return on equity of -223.63%.

Cryo-Cell International, Inc. has a consensus price target of $8.50, signalling upside risk potential of 149.27%. On the other hand P3 Health Partners, Inc. has an analysts' consensus of $10.25 which suggests that it could grow by 303.54%. Given that P3 Health Partners, Inc. has higher upside potential than Cryo-Cell International, Inc., analysts believe P3 Health Partners, Inc. is more attractive than Cryo-Cell International, Inc..

Cryo-Cell International, Inc. has a beta of 0.689, which suggesting that the stock is 31.12% less volatile than S&P 500. In comparison P3 Health Partners, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cryo-Cell International, Inc. has a quarterly dividend of $0.15 per share corresponding to a yield of 19.06%. P3 Health Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International, Inc. pays 510.2% of its earnings as a dividend. P3 Health Partners, Inc. pays out -- of its earnings as a dividend.

Cryo-Cell International, Inc. quarterly revenues are $7.8M, which are smaller than P3 Health Partners, Inc. quarterly revenues of $345.3M. Cryo-Cell International, Inc.'s net income of $749.4K is higher than P3 Health Partners, Inc.'s net income of -$69.5M. Notably, Cryo-Cell International, Inc.'s price-to-earnings ratio is 498.00x while P3 Health Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International, Inc. is 0.87x versus 0.01x for P3 Health Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.